10-Q: BriaCell Faces Going Concern Doubt Amid Rising R&D Costs

BriaCell Therapeutics reports increased net loss and significant cash burn, raising substantial doubt about its ability to continue as a going concern, despite advancing its oncology pipeline.

Summary

• Net loss for the three months ended October 31, 2025, increased to $8,278,328, up from $5,829,276 in the same period of 2024.
• Research and development expenses surged to $6,683,643, compared to $3,665,341 in the prior year, driven by increased clinical trial activity.
• Cash and cash equivalents decreased significantly to $2,714,012 as of October 31, 2025, from $10,493,808 on July 31, 2025.
• Net cash used in operating activities for the quarter was $7,704,796, an increase from $6,955,076 in the comparable prior-year period.
• The company's accumulated deficit reached $119,953,129 as of October 31, 2025.
• BriaCell is advancing its Bria-IMT pivotal Phase 3 study in metastatic breast cancer, with 79 clinical sites enrolling patients and a fourth consecutive positive safety recommendation from the DSMB.
• The Bria-OTS personalized immunotherapy program is progressing, with one patient showing complete resolution of a lung metastasis.
• BriaCell received a US$2.0 million SBIR grant from the U.S. National Cancer Institute for its Bria-PROS+ prostate cancer program.
• The company completed a 1-for-10 reverse stock split on August 25, 2025, primarily to maintain Nasdaq listing compliance.

Sentiment

Score: 3

Explanation: While clinical progress is promising with positive trial data and non-dilutive funding, the severe financial deterioration, including a significant increase in net loss, rapid cash burn, and an explicit 'going concern' warning, creates substantial financial risk that overshadows the operational positives.

Positives

• Bria-IMT pivotal Phase 3 study in metastatic breast cancer is advancing, with 79 clinical sites actively enrolling patients across 23 U.S. states.
• The independent Data Safety Monitoring Board (DSMB) issued a fourth consecutive positive recommendation for the Bria-IMT Phase 3 trial, identifying no safety concerns and recommending continuation without modification.
• Bria-IMT holds Fast Track Designation from the U.S. FDA, potentially accelerating the review process.
• Positive biomarker data from the Bria-IMT Phase 3 study will be presented at the ESMO 2025 Congress, showing trends similar to the Phase 2 study and an association between delayed-type hypersensitivity response and longer progression-free survival.
• The Bria-OTS personalized off-the-shelf immunotherapy program showed promising early results, with the first patient treated with a single agent demonstrating complete resolution of a lung metastasis.
• BriaCell was awarded a US$2.0 million Small Business Innovation Research (SBIR) grant from the U.S. National Cancer Institute (NCI) for its Bria-PROS+ prostate cancer program, providing non-dilutive funding.
• Collaboration with Memorial Sloan Kettering Cancer Center's (MSK) Therapeutics Accelerator Cohort program for the Bria-OTS+ platform, including support for manufacturing, IND development, and clinical protocol work for a planned Phase 1 study of Bria-BRES+.
• Financial income, net, increased significantly to $158,646 for the quarter, primarily due to higher interest income and an unrealized gain on short-term investments.

Negatives

• Net loss for the three months ended October 31, 2025, increased to $8,278,328, compared to $5,829,276 for the same period in 2024.
• Cash and cash equivalents decreased substantially from $10,493,808 on July 31, 2025, to $2,714,012 on October 31, 2025.
• Net cash used in operating activities increased to $7,704,796 for the quarter, up from $6,955,076 in the prior year.
• Total shareholders' equity decreased significantly from $17,334,046 on July 31, 2025, to $9,350,404 on October 31, 2025.
• Working capital decreased from a positive balance of $15,948,588 on July 31, 2025, to $8,030,634 on October 31, 2025.
• The accumulated deficit grew to $119,953,129 as of October 31, 2025, indicating continued operating losses.
• No cash was generated from financing activities during the three months ended October 31, 2025, compared to $11,960,252 in the prior year, highlighting a lack of recent capital infusion.

Risks

• The company's ability to continue as a going concern is dependent upon its ability to attain future profitable operations and to continue to obtain the necessary financing to meet its obligations, casting substantial doubt on its ability to continue.
• There is no assurance that the company will be able to raise additional capital through debt or equity financings.
• If additional capital is not raised, the company may need to curtail or cease its operations and implement a plan to extend payables or reduce overhead.
• The company has sustained operating losses and expects such losses to continue in the foreseeable future.

Future Outlook

The company expects operating losses to continue in the foreseeable future as it devotes substantial efforts to research and development activities. An interim overall survival analysis in the pivotal Phase 3 trial for Bria-IMT is expected in the first half of 2026. The company intends to raise additional capital to fund its operations and achieve business plan objectives, but there is no assurance of success.

Management Comments

• Management believes that the estimates, judgment and assumptions used are reasonable based upon information available at the time they are made.
• Management believes that it can be successful in obtaining additional capital; however, there can be no assurance that the Company will be able to do so.
• Certain directors and officers agreed to defer payment of their directors fees/compensation until we completed a financing, after which, these fees were paid in full.
• Certain officers have indicated their willingness to receive a portion of their compensation in equity of the Company, subject to applicable Nasdaq rules.
• We continue to reduce expenditure on certain non-core activities whilst maintaining our focus on our Phase 3 Bria-IMT pivotal study in advanced metastatic breast cancer.

Industry Context

BriaCell operates in the highly competitive and capital-intensive immuno-oncology biotechnology sector. Its focus on targeted immunotherapies for breast and prostate cancer, particularly with Fast Track Designation for Bria-IMT, positions it in a high-potential, high-risk segment. The collaboration with Memorial Sloan Kettering Cancer Center and the NCI grant indicate external validation and support for its scientific approach, which is crucial for clinical-stage biotech companies. However, the significant cash burn and going concern warning are common challenges for companies in this stage, where substantial investment is required before potential commercialization.

Comparison to Industry Standards

• BriaCell reported benchmark-beating patient survival and clinical benefit in metastatic breast cancer with median overall survival of 13.4 months in its Phase 2 study of Bria-IMT combination with retifanlimab, compared to 6.7-9.8 months for similar patients reported in the literature.
• Median overall survival of 16.5 months was observed in Phase 2 Bria-IMT study patients treated in combination with immune checkpoint inhibitor using the Phase 3 formulation since 2022 (post-COVID), indicating strong efficacy signals relative to historical controls.
• The first patient treated with Bria-OTS (single agent) demonstrated complete resolution of a lung metastasis, which is a significant early clinical signal for a personalized immunotherapy, though from a single case.

Corporate Governance

Related Party Transactions

• The company has a 65% ownership interest in BC Therapeutics, Inc., which is accounted for using the equity method. During the three-month period ended October 31, 2025, the company funded BC Therapeutics with $75,000 and recognized a share of losses of $44,830.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from potential future capital raises and the impact of reverse stock splits. The 'going concern' warning poses a substantial risk to investment value, despite promising clinical pipeline developments.
• **Employees/Management**: Stock options, RSUs, and PSUs granted align incentives with company performance. However, the 'going concern' uncertainty could impact job security and the value of equity compensation.
• **Customers (future patients)**: Continued clinical progress in Bria-IMT, Bria-OTS, and Bria-PROS+ offers hope for novel cancer treatments, particularly for metastatic breast and prostate cancer.
• **Creditors**: The 'going concern' warning indicates increased risk regarding the company's ability to meet its financial obligations in the long term.
• **Suppliers/Partners**: Ongoing collaborations (e.g., MSK, NCI, Receptor.AI) are positive, but the company's financial instability could impact its ability to sustain these partnerships or pay for services.

Next Steps

• Present positive biomarker data from the Bria-IMT Phase 3 trial at the ESMO 2025 Congress.
• Continue enrolling patients in the Bria-IMT pivotal Phase 3 study across 79 clinical sites.
• Await top-line data from the Bria-IMT Phase 3 study, expected as early as the first half of 2026, subject to event accrual.
• Conduct an interim overall survival analysis in the pivotal Bria-IMT Phase 3 trial, expected in the first half of 2026.
• Advance the Bria-OTS and Bria-OTS+ platforms for personalized off-the-shelf immunotherapies.
• Continue GMP manufacturing of lead candidates Bria-BRES+ and Bria-PROS+ in preparation for clinical trials.
• Progress with IND development and clinical protocol work for a planned Phase 1 study of Bria-BRES+ in breast cancer.
• Apply Receptor.AI's artificial intelligence platform to design highly selective anti-cancer kinase inhibitor candidates through the BriaPro Therapeutics Corp. subsidiary.
• Explore additional sources of capital and financing to fund operations and meet obligations.

Key Dates

Recommendation

Despite promising clinical advancements and non-dilutive funding, the company's financial position has deteriorated significantly, evidenced by a substantial increase in net loss, rapid cash burn, and a drastic reduction in cash and working capital. The explicit 'substantial doubt on the Company's ability to continue as a going concern' is a critical red flag for seasoned investors and institutions. While the pipeline holds potential, the immediate and severe financial instability, coupled with the absence of recent financing, makes the stock a high-risk investment. Prudent capital preservation dictates a 'sell' recommendation until a clear and sustainable financing path is established.

Keywords

BriaCell Therapeutics, BCTX, oncology, immunotherapy, breast cancer, prostate cancer, Phase 3 clinical trial, Bria-IMT, Bria-OTS, Bria-PROS+, SEC filing, 10-Q, biotechnology, cancer treatment, clinical stage, going concern